A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma

Investigational New Drugs

Volumn 20, Issue 3, 2002, Pages 357-362

  Pierson, A Scott ^a   Gibbs, Peter ^a   Richards, Jon ^b   Russ, Paul ^a   Eckhardt, S Gail ^a   Gonzalez, Rene ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b Lutheran General Cancer Center   (United States)

Author keywords

Irofulven; Melanoma; MGI 114

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ALPHA INTERFERON; HISTAMINE; INTERLEUKIN 2; ANTINEOPLASTIC ANTIBIOTIC; IROFULVEN; LACTATE DEHYDROGENASE; SESQUITERPENE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; HUMAN; MALE; MELANOMA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; BLOOD; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; HUMAN; LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGE; SESQUITERPENES; HUMANS; L-LACTATE DEHYDROGENASE; MIDDLE AGED;

EID: 0036021255     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016261918256     Document Type: Article

References (25)

1. Chemotherapy for metastatic melanoma
2. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy
3. Current therapy for malignant melanoma
4. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma
5. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study
6. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma
7. Multi institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma
8. Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells: Unusually high sensitivity in ERCC2 and ERCC3 DNA helicase-deficient mutants compared to other chemotherapeutic agents
9. waf expression
10. Preclinical evaluation of illudins as anticancer agents: Basis for selective cytotoxicity
11. In vitro and in vivo studies on the anticancer activity of dehydroilludin M
12. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
13. In vivo activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF) in various human tumor xenograft models including several lung and gastric tumors
14. Clinical trials
15. Phase II trial of carboplatin in patients with advanced melanoma
16. A phase II trial of weekly edatrexate (10-EDAM) in metastatic melanoma: A National Cancer Institute of Canada Clinical Trials Group Study
17. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trial Group
18. Zeniplatin in advanced malignant melanoma and renal cancer: Phase II studies with unexpected nephrotoxicity
19. Phase II trial of doxil for patients with metastatic melanoma refractory to front line therapy
20. Treatment of patients with metastatic melanoma with bryostatin-a phase II study
21. MGI-114: Augmentation of antitumor activity when combined with topetecan
22. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topetecan or paclitaxel in the MV522 lung carcinoma xenograft model
23. Anti-leukemic action of the novel agent MGI-114 (HMAF) and synergistic action with topetecan
24. Enhanced activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model
25. Phase II trial of topotecan in malignant melanoma